Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma

2016132 citationsJournal Article

Authors

Agnieszka Korfel · Charité - Universitätsmedizin Berlin

Uwe Schlegel · Charité - Universitätsmedizin Berlin

Ulrich Herrlinger · Charité - Universitätsmedizin Berlin

Martin Dreyling · Charité - Universitätsmedizin Berlin

Christian Schmidt · Charité - Universitätsmedizin Berlin

L. von Baumgarten · Charité - Universitätsmedizin Berlin

Antonio Pezzutto

Abstract

Single-agent temsirolimus at a weekly dose of 75 mg was found to be active in relapsed/refractory patients with PCNSL; however, responses were usually short lived.

Topics & Keywords

CNS Lymphoma Diagnosis and Treatment Lymphoma Diagnosis and Treatment Acute Myeloid Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 34, Issue 15, pp. 1757-1763

DOI: 10.1200/jco.2015.64.9897

Field-Weighted Citation Impact: 9.42